Author(s):
Lakshmi Usha Ayalasomayajula, M. Kusuma Kumari, Radha Rani Earle
Email(s):
alakshmiusha@gmail.com
DOI:
10.52711/2321-5844.2021.00002 
Address:
Lakshmi Usha Ayalasomayajula*, M. Kusuma Kumari, Radha Rani Earle
Department of Pharmaceutics, Maharajah’s College of Pharmacy, Vizianagaram, A.P., India.
*Corresponding Author
Published In:
Volume - 12,
Issue - 1,
Year - 2021
ABSTRACT:
In the recent days about 75% of the drugs taken orally are does not show the desired therapeutic effect. Oral conventional dosage forms have several disadvantages such as poor bioavailability due to hepatic first pass metabolism and tendency to produce rapid blood level spikes (Both high and low). Thus, rapid drug levels in the plasma leads to a need of high and/or frequent dosing, which can be both uneconomical and inconvenient. To overcome such disadvantages transdermal drug delivery system was developed. TDDS is such a delivery system which has been explored extensively over the last two decades, with therapeutic success. Transdermal drug delivery systems (TDDS) are the drug delivery systems which involves transportation of drug to epidermal and dermal tissues of the skin for local therapeutic action while major fraction of the drug is transported into the systemic blood circulation. Topical administration of therapeutic agents offers vast advantages over conventional oral and invasive methods of drug delivery. Some of the advantages of transdermal drug delivery include limitation of hepatic first pass metabolism, enhancement of therapeutic efficiency and maintenance of steady state plasma level concentration of the drug. This study includes a brief overview of TDDS, its advantages over conventional dosage forms, drug delivery routes across human skin, permeation enhancers, and classification, formulation, methods of preparation and evaluation of transdermal patches.
Cite this article:
Lakshmi Usha Ayalasomayajula, M. Kusuma Kumari, Radha Rani Earle. An Insight into delivery of drug through The Skin: Transdermal Drug Delivery system. Research Journal of Topical and Cosmetic Sciences. 2021; 12(1):4-2. doi: 10.52711/2321-5844.2021.00002
Cite(Electronic):
Lakshmi Usha Ayalasomayajula, M. Kusuma Kumari, Radha Rani Earle. An Insight into delivery of drug through The Skin: Transdermal Drug Delivery system. Research Journal of Topical and Cosmetic Sciences. 2021; 12(1):4-2. doi: 10.52711/2321-5844.2021.00002 Available on: https://rjtcsonline.com/AbstractView.aspx?PID=2021-12-1-2
REFERENCES:
1. Mahato RA. Pharmaceutical dosage forms anddrug delivery’’ Published by CRS press, Taylor and Froncrs Group, 6000 Broken Sound Parkway, Sute 300, Boca Raton, 2002, 196-197.
2. Hadgraft J. Skin, the final frontier. Int J Pharm. 2001; 224(1–2): 1–18.
3. Joseph R, Robinson, Vincent HL. Controlled drug delivery fundamentals and applications. Revised and Expanded: Lee. Marcel Dekker, Inc; 2005. p.524.
4. Moser K. Passive skin penetration enhancement and its quantification in-vitro. Eur J Pharm Biopharm. 2001; 52:103-112.
5. Aggarwal G. Development, Fabrication and Evaluation of Transdermal Drug Delivery‐ A Review. Pharmainfo.net. 2009.
6. Hanumanaik M, Patil U, Kumar G, Patel S K, Singh I, Jadatkar K, Design, Evaluation and Recent Trends in Transdermal Drug Delivery System: A Review, IJPSR, 2012; Vol. 3(8): 2393-2406
7. Chandrashekhar N S, Shobha Rani R H. Physicochemical and Pharmacokinetic Parameters in Drug Selection and Loading of Transdermal Drug Delivery. Indian Journal of Pharmaceutical Sciences. 2008; 70(1): 94‐96.
8. Levin G, Kornfeld J, Patel Y R, Damon S. Transdermal Delivery: Success Through A Deep Understanding of The Skin. Corium.
9. Shah S. Transdermal Drug Delivery Technology Revisited: Recent Advances. Pharmainfo.neGuy RH, Hadgraft J, editors. New York: Marcel Dekker; 2003. Transdermal Drug Delivery.
10. Williams A. London: Pharmaceutical Press; 2003. Transdermal and Topical Drug Delivery.
11. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov. 2004; 3: 115–124.
12. Bronaugh RL, Maibach HI, editors. Edn. 4th. New York: Marcel Dekker; 2005. Percutaneous Absorption.
13. Miller MA, Pisani E. The cost of unsafe injections. Bull World Health Organ. 1999; 77: 808–811.
14. Foldvari M, Babiuk S, Badea I. DNA delivery for vaccination and therapeutics through the skin. Curr Drug Devil. 2006; 3: 17–28.
15. Glenn GM, Kenney RT. Mass vaccination: solutions in the skin. Curr Top Microbiol Immunol. 2006; 304: 247–268.
16. Valenta, C. and Almasi-Szabo, I. (1995). In vitro diffusion studies of ketoprofen transdermal therapeutic system. Drug Dev.Ind. Pharm, 21: 1799-1805.
17. Krishna, R. and Pandit, J.K. (1994). Transdermal delivery of propranolol. Drug Dev.Ind. Pharm, 20: 2459- 2465.
18. Aqil, M., Zafar, S., Ali, A. and Ahmad, S. (2005). Transdermal drug delivery of labetolol hydrochloride: system development, in vitro; ex vivo and in vivo characterization. Curr Drug Deliv, 2(2): 125-31.
19. Shin, S. and Lee, H. (2002). Enhanced transdermal delivery of triprolidine from the ethylene-vinyl acetate matrix. Eur. J. Pharm. Biopharm, 54: 161-164.
20. Sweetman S.C. (2005). Martindale – The Complete Drug Reference. Foco A, Hadziabdic J, Becic Transdermal drug deliverysystems. Med. Arch 2004; 58: 230-4.
21. Khatun M, Islam ASM, Akter P, Quadir AM, Reza SM. Controlled release of naproxen sodium from eudragit RS100 transdermal film, Dhaka University. J. Pharm. Sci. 2004; 3(1-2).
22. Rao PR, Diwan PY. Permeability studies of cellulose acetate free films for transdermal use: Influence of plasticizers. Pharm. Acta. Helv. 1997; 72: 47-51.
23. Gondaliya D, Pundarikakshudu K. Studies in formulation and pharmacotechnical evaluation of controlled releasetransdermal delivery system of bupropion. AAPS. Pharm.Sci. Tech. 2003; 4: Article3.
24. Swarbrick J, Boylan J. Encyclopedia of Pharmaceutical Technology: “Transdermal drug delivery devices: systemdesign and composition”: 309-37.
25. Singh J, Tripathi KT, Sakia TR. Effect of penetration enhancers on the in vitro transport of ephedrine throughrate skin and human epidermis from matrix basedTransdermal formulations. Drug. Dev. Ind. Pharm. 1993; 19: 1623-8.
26. Wade A, Weller PJ. Handbook of pharmaceutical Excipients. Washington, DC: American Pharmaceutical Publishing Association; 1994. p.362-366.
27. Reddy RK, Muttalik S, Reddy S. Once daily sustainedrelease matrix tablets of nicorandil: formulation and in vitro evaluation. AAPS. Pharm. Sci. Tech. 2003; 4: 4.
28. Shaila L, Pandey S, Udupa N. Design and evaluation of matrix type membrane controlled Transdermal drug delivery system of nicotin suitable for use in smoking cessation. Indian. Journ. Pharm. Sci. 2006; 68: 179-84.
29. Aarti N, Louk ARMP, Russsel OP, Richard HG. Mechanism of oleic acid induced skin permeation enhancement invivo in humans. Jour. control. Release. 1995; 37: 299-306.
30. Lec ST, Yac SH, Kim SW, Berner B. One way membrane for transdermal drug delivery systems/system optimization.Int. J. Pharm. 1991; 77: 231-7.